Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina

Phase 4

Withdrawn

• Conditions: Angina Pectoris; Diabetes Mellitus, Type 2

• Registration Number: NCT00225342
• Lead Sponsor: University of Glasgow

Brief Summary

The principle objective of the trial is to compare rosiglitazone to gliclazide in patients with type 2 diabetes mellitus and chronic stable angina to see how the subjects' angina status changes.

Angina status will be measured via exercise tolerance testing, 24-hour ECG testing and angina quality of life questionnaire.

Detailed Description

Ischaemic heart disease is one of the main complications of type 2 diabetes mellitus, both in terms of morbidity and mortality. Reducing plasma glucose with hypoglycaemic agents has not been shown to improve cardiovascular mortality or morbidity. Chronic stable angina is a common problem in patients with type 2 diabetes mellitus.

We postulate that in subjects with uncontrolled type 2 diabetes mellitus (Hba1c \>7.5%), on metformin therapy, and chronic stable angina that the addition of the insulin sensitiser, rosiglitazone to control their diabetes will improve their angina when compared to the addition of the hypoglycaemic agent gliclazide. This hypothesis is based on the fact that insulin resistance is an upstream mechanism common to both conditions.

We will randomise such patients to 3 months therapy of rosiglitazone or gliclazide for 3 months, comparing angina status before and after by way of full Bruce protocol exercise testing, 24 hour ST segment analysis and angina questionnaire.

Study Timeline

• Status Verified: 2005-09
• Study First Submitted: 2005-09-21
• Study First Submitted QC: 2005-09-21
• Study First Posted: 2005-09-23
• Last Update Submitted: 2006-09-07
• Last Update Posted: 2006-09-08

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Chronic stable angina with ongoing symptoms. (The treatment goal being an improvement in symptoms)
• Participants will have uncontrolled diabetes (Hba1c>7.5) on metformin monotherapy (so the diabetes is not over treated)
• Participants will be diabetic for less than 8 years.

Exclusion Criteria

• Renal impairment (creatinine >130mmol/l)
• Hepatic Impairment (ALT>70U/l, AST>80U/l)
• Any clinical signs of heart failure
• Physical disability precluding treadmill exercise tolerance testing
• Abnormal resting ECG (left or right bundle-branch block, left or right ventricular hypertrophy, ventricular preexcitation, Q-wave myocardial infarction, digitalis therapy)
• Women of childbearing potential
• Women who are breastfeeding

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Angina status at 3 months

Secondary Outcome Measures

Name	Time	Method
Small vessel function at 3 months
Biochemical markers of inflammation at 3 months
Pulse wave velocity at 3 months
Haemostatic markers at 3 months

Trial Locations

Locations (1)

Cardiology Department, Glasgow Royal Infirmary; 🇬🇧 Glasgow, United Kingdom